Endosperm-specific expression of human acid beta-glucosidase in a waxy rice
© Patti et al.; licensee Springer. 2012
Received: 7 August 2012
Accepted: 27 November 2012
Published: 6 December 2012
The deficiency of human acid beta-glucosidase (hGCase) causes Gaucher disease, a rare genetically-inherited disorder currently treated by enzyme replacement therapy using recombinant CHO-derived GCase. In an attempt to provide an alternative and more efficient production system, a chimeric cDNA coding for hGCase operatively linked to the signal peptide of rice glutelin 4 (GluB4) was put under the control of the GluB4 endosperm-specific promoter and inserted into the genome of a waxy rice.
Molecular, immunological and biochemical analyses showed that recombinant hGCase, targeted to the protein storage vacuoles of rice endosperm cells, is equivalent to the native protein and has a glycosylation pattern compatible with direct therapeutic use. Compared to a previous study carried out on transgenic tobacco seeds, enzyme contents per unit of biomass were drastically increased; in addition, differently from what observed in tobacco, rice seed viability was unaffected by hGCase even at the highest production level. Transgenic seed polishing combined with a pretreatment of seed flour greatly facilitated hGCase extraction and purification with an industrially-scalable procedure.
This study opens up the possibility to efficiently produce in the rice seed pharmaceutical compounds which are available in limited amounts or completely excluded from clinical practice due to the inadequacy of their production systems.
KeywordsHuman acid beta-glucosidase Gaucher disease Transgenic rice Pharmaceutical proteins Endosperm-specific expression Molecular farming
Human acid beta-glucosidase (hGCase; EC 22.214.171.124) catalyzes the hydrolytic cleavage of glucose from glucosylceramide in lysosomes (Brady et al.1965). It is a homomeric glycoprotein of 497 amino acids with a molecular mass ranging from 60 to 68 kDa, containing five putative N-glycosylation sites, four of which are normally occupied (Berg-Fussman et al.1993; Brumshtein et al.2006). The quantitative/qualitative deficiency of hGCase leads to an accumulation of glucosylceramides in lysosomes and causes the Gaucher disease (GD), one of the most frequent human sphingolipidosis. Fatty material can collect in the spleen, liver, kidneys, lungs, brain and bone marrow. Main clinical symptoms may include hepatosplenomegaly, anaemia, thrombocytopenia and skeletal deterioration (2001). GD has a pan-ethnic diffusion but its frequency is particularly high (1:640 to 1:10,000) in the Ashkenazi Jewish population (Beutler and Grabowsky2001;1997), whereas in the non-Jewish population data are varying from 1:57,000 to 1:200,000 (Cox and Schofield1997; Meikle et al.1999).
GD is currently treated by enzyme replacement therapy (ERT) using mainly a recombinant processed form of human acid beta-glucosidase (commercial imiglucerase) obtained from cultured CHO cells. Regular infusions of the missing enzyme were found effective in reducing the visceral and bone marrow storage of glucosylceramides, decreasing spleen and liver volumes, normalizing/stabilizing hematochemical parameters (Hb, platelets, hepatic enzymes, chitotriosidase) and improving the quality of life of GD patients (Grabowski et al.1995; Damiano et al.1998). However, the current production system based on CHO is economically very expensive and limits the drug amounts present on the market, seriously hindering the maintenance and the diffusion of therapeutic regimes.
Moreover, an acute shortage of commercial imiglucerase has recently occurred as a result of viral contamination of the production facility, forcing all countries to reassess their stocks and to establish new priorities of drug supply to patients (Hollak et al.2009).
Although an additional two enzymatic forms were approved for early access clinical programs, i.e. velaglucerase alpha (from cultured human fibroblasts; Aerts et al.2010) and taliglucerase alpha (from cultured carrot cells; Shaaltiel et al.2007, Aviezer et al.2009), the drug shortage has underlined the necessity to find a valid alternative production system to guarantee sufficient drug supply to patients not only for Gaucher disease, but also for other disorders and diseases curable with lifelong therapies.
Molecular farming, i.e. the production of valuable recombinant proteins in plants (Schillberg et al.2003), can represent a good solution to this need, because plants have several advantages over traditional platforms for recombinant pharmaceutical protein production. Plants are inexpensive, they are highly scalable, they offer high product quality and they do not support human pathogens. Crops producing pharmaceutical molecules can be established with minimal upfront investment in infrastructures, unlike the major fermentation-based platforms (Fischer et al.2012).
Concerning Gaucher disease, in a previous study, a procedure for production and immuno-purification of human acid beta-glucosidase in tobacco seeds was developed (Reggi et al.2005). The plant-derived enzyme was found stable, active and taken up by human target cells; nevertheless, it was also found that the best transgenic lines could not be maintained through sexual reproduction due to seed non viability; this fact combined with the tiny dimensions and the high lipid content of tobacco seed had a negative impact on industrial scalability.
The present paper describes a novel technological platform for the large-scale production of recombinant human GCase (rhGCase) in the endosperm of Oryza sativa L. In the new system, seed germination is not impaired by the recombinant enzyme, protein extraction and purification can be easily performed with resins available in bulk amounts and the product quality appears largely suitable for therapeutic purposes.
Rice transformation and molecular analyses on primary transformants
Western blot analyses on seed protein extracts
The Western blot signal intensity differed among lines; since in a previous study the band intensity was found correlated with rhGCase content (Reggi et al.2005), Western blotting was used to select the best primary transformants, until a consistent ELISA was developed. The protein extracts of 18 transformants repeatedly gave better results; this superiority was confirmed in Western blot analyses carried out using different sample dilutions. Best transformants were grown to produce a T2 generation for further quantitative analyses, whereas the seed of the remaining lines was bulked and used to develop the GCase purification procedure.
Subcellular localization of recombinant GCase
Tissue-specific expression analyses
rhGCase extraction and purification
DAS-ELISA was also used to determine the rhGCase content in polished rice flour derived from a bulk of unselected seeds harvested from the best primary transformants. The overall estimated yield was 143 mg of rhGCase per kg of flour.
Efficiency of chromatographic steps in rhGCase purification
Cumulative GCase loss
Removal of contaminants
Peptide mass fingerprinting and N-terminal sequencing
The identity of the rhGCase N-terminal sequence was also determined through conventional Edman analysis. The resulting data confirmed that the first 9 amino acids of rhGCase correspond exactly to the first tract of the human mature polypeptide. Hence, it was demonstrated again that the signal peptide of glutelin 4 is well recognized and properly removed from the precursor protein during traslocation in the ER.
Glycan structure analyses
Among different methods described for the production of recombinant proteins in plants, those involving the seed are particularly attractive because seeds are natural organs devoted to the production and accumulation of storage proteins in a small volume and in a stable biochemical environment. In particular, neo-synthesized proteins are targeted to subcellular storage compartments such as protein bodies and protein storage vacuoles, where they can be preserved for a long time due to a low water content and the presence of proteinase inhibitors (Takaiwa et al. 2007).
In former experiments (Reggi et al. 2005), it was demonstrated that recombinant human GCase can be stored in a stable and active form in tobacco seed. However, in the best primary transformants, seed viability appeared totally impaired and all attempts to overcome the problem were unsuccessful (Reggi et al.2005). This evidence, together with a high oil content and tiny dimension of tobacco seed, prompted us to consider rice as an alternative host-species.
In seed-specific expression studies carried out in tobacco, recombinant proteins are typically accumulated in the cotyledon parenchymatic tissue, hence they can directly interfere with embryo development and seed germination. Differently, in rice there is the opportunity to allocate recombinant proteins in the endosperm, i.e. a tissue separated by the embryo and metabolically inert at maturity. Beside this, rice seeds can be industrially processed to separate the hulls, the germ and the aleuronic layer. The removal of these components, which is relatively inexpensive, greatly favours the extraction and purification of heterologous proteins because both the lipid content and the number of protein contaminants are minimized.
Among other advantages in using rice as bioreactor, there is the availability of some non-food varieties with easily-recognizable genetic markers (Takaiwa et al. 2007). In this work, essentially for biosafety issues, the japonica waxy rice CR W3 was used; CR W3 is a registered variety with round-shaped seed developed by the Rice Research Centre of Ente Nazionale Risi (Milan, Italy) but insofar awaiting commercial exploitation. Due to an almost void amylose content, CR W3 seed can be used for the production of starch and related byproducts, whereas its employment as human food is difficult for the remarkable loss of consistency with boiling.
The endosperm-specific accumulation of rhGCase in CR W3 seed was gained through the use of the rice glutelin 4 promoter (GluB4pro). In a former study carried out with different seed-specific promoters (Qu and Takaiwa 2004), GluB4pro determined the highest level of GUS expression in transgenic rice. The maximum accumulation of the GUS protein was observed in the inner starchy endosperm, close to the late maturation stage.
In our experiments, GluB4pro showed a similar expression pattern: in fact, rhGCase was detected exclusively in the seed endosperm and not in other vegetative or reproductive tissues; moreover, SDS-PAGE and Western blotting analyses indicated that only negligible amounts of rhGCase are lost with seed polishing, a process that eliminates the germ and the aleuronic/sub-aleuronic layers (Figure 6).
Much interestingly, neither seed viability nor dormancy were affected by rhGCase endosperm-specific expression; in all instances percent viability was excellent (99-100%) and resembled that of untransformed control. These data clearly demonstrate that the problem of seed viability loss recorded for tobacco plants (Reggi et al.2005) is non-existent in rice.
It is important to underline that, despite seed protein content is significantly lower in rice compared to tobacco, in rice endosperm rhGCase expression levels were found much greater than those recorded in the best tobacco transformants, perhaps due to more permissive physiological conditions and the triploid nature of the tissue. The achievement of high transgene expression levels is crucial for developing a technological platform for industrial scale-up; beside promoters, several molecular elements must be considered, including 5’ UTR and the signal peptide sequence for specific subcellular localization. For the purpose of this study, the GluB4 native leader was replaced with the artificial leader LLTCK (De Amicis et al.2007) mainly characterized by the combination of a poly(CAA) region with a CT-rich motif. In previous studies, the LLTCK leader determined a 12.5-fold enhancement of uid A expression in tobacco leaf as compared with the native CaMV 35S leader sequence (De Amicis et al.2007). No experimental evidence about the utility of LLTCK in monocot plants has been published so far; it should be noted however that, although not in association between each other, CT- and GA-rich regions occur in the proximity of the transcription start site of many plant genes, particularly in monocots (Chen et al.1996).
As far as subcellular targeting is concerned, its influence on folding, assembling, post-translational modifications and stability of a protein is widely recognized (Twyman et al.2003; Doran2006; Benchabane et al.2008). In this study, the signal peptide of glutelin 4 (SPGluB4) was used; immunolabelling results demonstrated that this SP determined a rhGCase accumulation in the same storage compartment of GluB4, i.e. the protein storage vacuoles (PSVs) (Takaiwa et al.1999; Kawakatsu et al.2008).
Similarly to other PSV-allocated recombinant proteins (Humphrey et al.2002; Arcalis et al.2004; Vitale and Pedrazzini2005), both rhGCase content and activity were maintained unaltered after 12 months of storage (data not shown).
The use of a signal peptide for ER-targeting is an acquainted technology; a more challenging aspect is represented by the prediction of both SP removal and cleavage site. If the SP is not separated from the protein, the precursor-complex can remain anchored to the ER outer membrane (Yan et al.1997) and in any case it does not assume the correct tertiary structure. On the other hand, if the SP is removed but cleavage does not occur in the exact position, different non-authentic versions of the mature protein may arise. This condition is absolutely detrimental for therapeutic proteins since mutated forms are potentially immunogenic or provided with different pharmacodynamic properties. Some software tools were devised for prediction of the SP cleavage site in different host systems (Emanuelsson et al.2007). In the present work, both SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP) and SIG-PRED (http://bmbpcu36.leeds.ac.uk/prot_analysis/Signal.html) were preliminary used to determine the probability of proteolytic cleavage of SPGluB4/GCase complex; in either case, the predicted site corresponded exactly to the boundary between SPGluB4 and mature GCase (MATIAFSRLSIYFCVLLLCHGSMA//ARPCIPKSF…). In fact, N-terminal sequencing revealed that SPGluB4 is well recognized and correctly removed, thus originating a mature protein whose amino acid sequence is perfectly identical to the human one.
Another important issue for injectable proteins produced in plants concerns the type and level of N-glycosylation. Glycan analyses performed by MALDI-TOF on oligosaccharide chains of rice-derived GCase revealed that 11 out of 12 predicted glycoforms are mannose-ending, which is an essential pre-requisite for human cell internalization. This represents a further advantage in the clinical use of rice-derived GCase in comparison with CHO-derived molecule. In fact, the latter must be partially deglycosylated in order to expose mannose residues which are specifically recognized by endocytic carbohydrate receptors on macrophages of reticulo-endothelial system. This enzymatic process complicates the purification step and increases production costs (Futerman et al.2004). Preliminary assays conducted on human target cells demonstrated that the rice seed-derived enzyme is well-recognized and taken up at levels comparable to those of the commercial imiglucerase (data not shown).
This paper describes an industrially-scalable method to produce human acid beta-glucosidase in rice endosperm. Likewise, the same procedure can be applied to efficiently produce pharmaceutical compounds which, similarly to rhGCase, are potentially harmful to the plant cell.
it allows a tissue-specific expression and a consistent subcellular localization of human acid beta-glucosidase inside the rice seed;
it allows the production of a pharmaceutical molecule suitable for therapeutic use;
it does not affect seed viability thus enabling the maintenance and multiplication of productive lines through sexual reproduction;
it facilitates both enzyme extraction and purification, improving the overall management of the productive process;
it is economically more convenient compared to the CHO-technology, thus setting the conditions for a more affordable therapy of Gaucher disease.
Rice-derived rhGCase displays all the molecular characteristics and pharmaceutical prerequisites for ERT of Gaucher disease, being highly equivalent to the native human enzyme.
Construction of the plant expression vector pTRS0_GCase
This vector was developed from the commercial plasmid pCAMBIA1300 [GenBank: AF234296] by introduction of the GCase cassette into the Eco RI site. The GCase cassette was designed to harbour the rice storage protein glutelin 4 promoter (GluB4pro), the human GCase CDS and the nopaline synthase terminator of Agrobacterium tumefaciens (NOS-ter).
The GluB4pro sequence was PCR-isolated from rice genomic DNA (Oryza sativa ssp. japonica, var. CR W3) with primers designed on the basis of GenBank acc. No. AY427571 (forward 5’- GCATGCGAATTCTACAGGGTTCCTTGCGTG-3’; reverse 5’-TCTAGAAGCTATTTGAGGATGTTATTGGAA-3’). In order to improve rhGCase expression levels, the native 5’-UTR was substituted with the LLTCK leader (De Amicis et al.2007). RhGCase targeting to the protein storage vacuoles (PSVs) was attempted with the transit peptide of rice glutelin 4 (Uniprot code P14614 [1–24]). Promoter, LLTCK leader and transit peptide sequences were ligated immediately upstream the GCase mature polypeptide CDS [GenBank: M16328, nt 553–2043]; the GCase coding sequence was obtained by RT-PCR from human placental total RNA. The expression cassette was completed by the addition of nos-ter.
Rice transformation and molecular analyses on primary transformants
The engineered vector was introduced into Agrobacterium tumefaciens, strain EHA105, by electroporation. Rice transformation was carried out according to Hiei et al. (1994) with minor modifications. Putatively transformed (i.e. hygromycin resistant) plants were potted in peat, hardened in a greenhouse and maintained until seed maturation. For PCR analyses, genomic DNA was extracted from young leaves according to Doyle and Doyle (1990) and analysed with two primer pairs (forward1 5’-TCTAGAATGGCCACCATTGC-3’ and reverse1 5’-GAGCTCTCACTGGCGATGCC-3’; forward2 5’-AATAGCTGCGCCGATGGTTT-3’ and reverse2 5’-ACCACGGCCTCCAGAAGAAG-3’) with the following PCR conditions: one cycle of 5 min at 95°C, 40 cycles of 40 s at 95°C, 40 s at 58°C and 2 min at 72°C, followed by a final extension step of 5 min at 72°C.
Primer pairs and probes used in real-time quantitative PCR
RT-PCR was performed with the thermal cycler iCycler iQ real-time PCR detection system (Bio-Rad) and 1xPlatinum Quantitative PCR SuperMix UDG (Invitrogen). The amplification conditions consisted of one cycle of 3 min at 50°C and 3 min at 95°C, followed by 50 cycles of 15 s at 95°C and 1 min at 60°C. In order to generate standard curves for DNA quantification, SPS- and GCase-harbouring plasmids were serially diluted and analyzed.
Protein extracts for Western blot analyses were prepared as follows: five dehulled seeds were ground with 1 mL of extraction buffer (500 mM NaCl in 50 mM Tris-HCl buffer, pH 7.0) using mortar and pestle. The resulting homogenate was incubated at RT for 5 min under agitation and then centrifuged at 15000 × g for 45 min at 4°C. The supernatant (30 μg soluble protein) was directly used for SDS-PAGE.
Protein extracts for ELISA analyses were obtained homogenizing five dehulled seeds with 10 mL extraction buffer, as above.
To determine rhGCase expression levels, 40 dehulled seeds were milled and thoroughly homogenized in 80 mL extraction buffer and stirred on ice for 1 h. The extract was centrifuged at 20000 × g, 4°C, for 40 min. The supernatant was collected and stored for DAS-ELISA.
Gel electrophoresis and staining
SDS-PAGE was performed under standard conditions, using the Mini Protean II apparatus (BioRad), loading the samples in 10% polyacrylamide gels after denaturation for 5 min. Commercial molecular weight markers (Fermentas) and commercial imiglucerase were used to assess the molecular weight of rhGCase. Gels were stained with EZBlueTM Gel Staining Reagent (Sigma Aldrich) or with ProteoSilverTM Silver Stain kit (Sigma Aldrich).
The extracts prepared as above were denaturated under non-reductive conditions and loaded in a 10% polyacrylamide gel together with Precision Protein Standard (BioRad). The gel was electroblotted to a 0.2 μm PVDF membrane (Millipore) with the Trans-blot SD apparatus (BioRad). The blot was blocked with 7.5% non-fat dry milk (Oxoid) in PBS for 1 h at RT. After 3 washes with PBS Tween 0.1%, the primary rabbit polyclonal antibody, produced using commercial imiglucerase (Genzyme Corp., Sanofi Aventis) as antigen, was diluted 1:1000 in the blocking buffer and the blot was incubated for 1 h at RT. Then, the HRP-conjugated secondary antibody (Sigma Aldrich) was diluted 1:10000 and the blot incubated again for 1 h at RT. After final washes, chemiluminescence was developed with ECL plus (GE Healthcare). To identify the best transgenic lines, samples showing a strong signal were further evaluated by Western blotting using two- or four-fold diluted supernatants.
RhGCase quantification by DAS-ELISA
A double antibody sandwich ELISA was used to quantify rhGCase in both crude protein extracts and chromatographic fractions. Capture antibody was obtained from the same rabbit antiserum used in Western analyses, purified by affinity chromatography on imiglucerase derivatized resin. Detecting antibody was produced by conjugating HRP with capture antibody. Both antibodies were purchased from Davids Biotechnologie (Germany).
SPL maxi binding plates (SPL, Korea) were coated with 2 ng/μL of capture antibody in coating solution (30 mM NaCl, 2.5 mM sodium phosphate buffer, 15 mM sodium azide, pH 7.4), 100 μL per well. Coating was performed by stirring the plate at 37°C for 20 min. Then, the plate was blocked with 3% BSA solution in PBS with 15 mM sodium azide, at 37°C for 20 min, 300 μL per well. Crude extracts were diluted 1:30 in dilution buffer (1% BSA, PBS-Tween 20 0.1% solution, pH 7.4), added to the plate and incubated at 37°C for 20 min, 100 μL per well. Chromatographic fractions were differently diluted case by case. After three washes with PBS-Tween 20 0.1%, detecting antibody was applied at 0.8 ng/μL in dilution buffer, 50 μL per well at 37°C for 20 min. After four washes, detection was performed using TMB Liquid substrate system (Sigma Aldrich), 100 μL per well; the reaction was stopped with 1 M HCl, 100 μL per well. Plates were read with Modulus II microplate reader (Turner Biosystem) at 450 nm.
For rhGCase quantification, a standard curve was built with the following commercial imiglucerase concentrations: 250, 125, 62.5, 31.3 15.6, 7.8, 3.9, 2.0 pg/μL in dilution buffer, 100 μL per well.
To evaluate rhGCase expression levels in polished seed, serial extracts were diluited 1:100 in ELISA dilution buffer and analyzed separately. The total rhGCase amount was calculated and expressed as mg per kg of flour.
Tissue-specific expression analyses
In order to demonstrate the endosperm-specific expression of rhGCase, Western blot analyses were performed on crude protein extracts obtained from different organs/tissues at the vegetative and reproductive stage. Protein samples were taken from: leaf blade, leaf sheath, stem internode, stem node, root, rachis, glume and husk, unfertilized ovule, immature anther, mature pollen, immature embryo, endosperm, using Tris-HCl 50 mM, 0.5 M NaCl, pH 7.0 in mortar and pestle. To extract proteins, the resulting homogenates were incubated on ice for 1 h under agitation and then centrifuged at 15000 × g for 45 min at 4°C. Protein concentration of the supernatants was determined by a standard Bradford assay (Bradford1976). Samples (7–15 μg) were loaded in Laemmli buffer (Laemmli1970) into a 10% polyacrylamide gel together with a molecular weight marker (Sigma Aldrich) and a positive control (commercial imiglucerase). At the end of the run, proteins were stained overnight with Coomassie and destained with 20% methanol and 10% acetic acid. A second electrophoretic gel was used to blot the proteins onto a PVDF membrane and perform a Western blot analysis as reported in the previous paragraph. SDS-PAGE and Western blotting were performed also on samples extracted from wild type CR W3. Results achieved by Western blotting were eventually confirmed in DAS-ELISA.
Electron and immunoelectron microscopy
Unlabeled osmium-treated samples were prepared according to Musetti et al. (2011). For immunoelectron microscopy, immature rice seeds (approx. 10–15 days after flowering) were fixed in 0.2% glutaraldehyde, rinsed in 0.1 M phosphate buffer, pH 7.4, dehydrated in ethanol (25, 50, 75%, 30 min each step, then 100% for 1 h), then infiltrated in LR White Resin (LRW, London Resin) with the following ratio: LRW:ethanol 1:2 for 30 min, LRW:ethanol 2:1 for 30 min, and 100% LRW (two changes: after 1 h, then overnight) at RT. The samples were embedded in fresh LRW resin in BEEM capsules and polymerized at 60°C for 24 h.
Ultra-thin sections (60–70 nm) were cut with the ultramicrotome LKB Nova (Reichter) and mounted on nickel grids (Electron Microscopy Sciences) for immunolocalization. Sections were incubated with Normal Goat Antiserum (Aurion) diluted 1:30 in buffer C (0.05 M Tris-HCl, pH 7.6, 0.2% BSA) for 15 min and then with the anti-GCase serum diluted 1:500 in buffer C for 1 h at RT. After washes, the sections were incubated for 1 h with a solution of goat anti-rabbit antibody conjugated with 15 nm colloidal gold (Aurion) diluted 1:40 in 0.02 M Tris-HCl, pH 8.2, containing 0.9% NaCl and 1% BSA. Sections were stained with 0.1% lead citrate (Reynolds1963) and examined with the CM10 transmission electron microscope (Philips).
One hundred non-vernalized seeds produced by the best transgenic lines were placed onto moistened paper and incubated in petri dishes at 28/22°C d/n, 16/8 h d/n; seeds were daily controlled to determine their viability using untransformed, non-vernalized CR W3 seed as control.
Transgenic rice seed was dehulled, polished with the TO-92 equipment (Satake) and milled in a coffee blender. Rice flour was suspended in cold methanol (1:5 w/v), stirred on ice for 5 min and centrifuged for 15 min at 14000 × g. After the supernatant was discarded, the pellet was extracted with 2 mM sodium citrate, pH 5.5 (1:5 w/v) and centrifuged for 15 min at 14000 × g; this step was done to eliminate the low-salt soluble protein fraction and for a better efficiency it was repeated twice. At the end of pretreatment, the pellet was extracted with 0.5 M NaCl in 50 mM Tris-HCl buffer, pH 7.0 (1:5 w/v). The extract was stirred for 5 min at RT and then centrifuged for 15 min at 14000 × g to recover the supernatant. In order to extract all the rhGCase protein stored in rice seed, the extraction procedure was repeated three times and the supernatants were pooled and further clarified by centrifugation at 14000 × g for 45 min at 4°C.
RhGCase was purified using a three-step purification process involving HIC (Hydrophobic Interaction Chromatography) for capture, IEC (Ion Exchange Chromatography) for intermediate purification and GF (Gel Filtration) for the polishing step. All chromatographies were performed with the AKTA Prime purification system (GE Healthcare).
For HIC, two 5-mL HiTrap Octyl FF columns (GE Healthcare) were serially connected and equilibrated with one column volume of loading buffer (10 mL of 200 mM ammonium sulphate in 50 mM Tris-HCl buffer, pH 7.0). A 3 M ammonium sulphate solution was added to the clarified extract to reach a final concentration of 200 mM ammonium sulphate. After filtration with 0.2 μm filter (Millipore), 300 mL of the extract were applied to the column at a 5 mL/min flow-rate. The flow-through was reloaded onto the column until three loading volumes were passed. The flow-through was then collected and stored until analysis. The column was washed with 14 column volumes (140 mL) of 15 mM sodium citrate buffer, pH 5.5. Elution was carried out by increasing ethylene glycol concentrations from 0% to 50% in 15 mM sodium citrate buffer, pH 5.5. One-mL fractions were collected and tested in ELISA. Positive fractions (from number 3 to number 15) were pooled and loaded in a 1-mL HiTrap SP HR column (GE Healthcare); rhGCase was eluted in 5-mL fractions by a continuous gradient from 60 mM to 200 mM of NaCl in 20 column volumes (20 mL).
Gel filtration was used as the final polishing step. A HiPrep 16/60 Sephacryl S-100 High Resolution column (GE Healthcare) was equilibrated with 15 mM sodium citrate and 150 mM NaCl, pH 5.5; the column was then loaded with the DAS-ELISA positive IEC fraction (number 3), reduced to 500 μL by Amicon Ultra-15 (MWCO 30 kDa, Millipore) and run at a flow-rate of 0.5 mL/min. In order to recognize the rhGCase-containing peak, a preliminary GF was performed with commercial imiglucerase.
RhGCase activity was assayed using 4-MUG (4-methylumbelliferyl β-D-glucoside, Sigma Aldrich) as substrate. The reaction buffer contained 100 mM sodium acetate buffer, pH 5.5, 0.5% w/v taurocholate and 10 mM 4-MUG, 50 μL per well. The reaction was carried out at 37°C for 30 min and finally stopped with 200 μL 100 mM glycine-NaOH, pH 10.0. Fluorescence was read at 410–460 nm with the fluorimeter Modulus II microplate reader (UV Optical kit, Turner Biosystem) following excitation at 365 nm. A standard curve was built with 2.5-5.0 nmol 4-MU (4-methylumbelliferone, Sigma Aldrich) in reaction buffer, 200 μL per well.
Peptide mass fingerprinting and N-terminal sequencing
Peptide mass fingerprinting was performed by MALDI-TOF technology (Perkin Elmer). A purified rhGCase sample was electrophoresed and stained with Coomassie Blue R-250 staining; the band of interest was cut, washed at 37°C with a 100 mM NH4HCO3 and acetonitrile (ACN) (50:50 v/v) solution, ground and dehydrated with ACN. The protein was reduced with 10 mM dithiothreitol, alkylated with 50 mM iodoacetamide (IAA) and overnight digested with 50 ng/μL trypsin (Promega) at 37°C. After a further treatment with 2% formic acid and 60% ACN, peptides were purified with a zip-tip C18 (Millipore), removing the contaminants with 0.1% TFA washes. Peptides were slowly eluted with ACN and 0.1% TFA (70:50), mixed with a CHCA (α-cyano-4-hydroxycinnamic acid) matrix and spotted onto a MALDI plate for analysis.
For N-terminal sequencing, a purified rhGCase sample was electrophoresed and blotted onto a PVDF membrane. The rhGCase band was identified by Coomassie-Blue staining. The N-terminal sequence was determined by Primm Srl (Milan, Italy) using the Edman degradation method (Edman1950).
Glycan structure analyses
Glycosylation patterns were determined using exoglycosidase digestion and MALDI-TOF analyses. In particular, a purified rhGCase sample was run on SDS-PAGE and the band of interest, identified by Coomassie-Blue staining, was cut out and incubated with PNGase F, i.e. peptide-N(4)-(N-acetyl-β-glucosaminyl) asparagine amidase F, to remove the oligosaccharide chains connected to the amidic group of asparagine residues. Oligosaccharide chains were then analysed by MALDI-TOF according to Siemiatkoski et al. (2006).
recombinant human acid-beta-glucosidase
enzyme replacement therapy
sucrose phosphate synthase
protein storage vacuoles
hydrophobic interaction chromatography
ion exchange chromatography
- PNGase F:
peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F
glutelin 4 promoter
signal peptide of glutelin 4.
We thank Dr. Gian Luca Bianchi and his staff of the biotechnologies laboratory of ERSA Plant Health, Agricultural Chemistry, Analysis and Certification Service (Pozzuolo del Friuli, Udine, Italy) for the real-time quantitative PCR analyses and Dr. Romano Gironi of the Rice Research Centre of Ente Nazionale Risi (Milan, Italy) for the CR W3 rice variety supply.
- Aerts JM, Yasothan U, Kirkpatrick P: Velaglucerase alfa. Nat Rev Drug Discov 2010, 9: 837–838. 10.1038/nrd3311View ArticlePubMed
- Arcalis E, Marcel S, Altmann F, Kolarich D, Drakakaki G, Fischer R, Christou P, Stoger E: Unexpected deposition patterns of recombinant proteins in post-endoplasmic reticulum compartments of wheat endosperm. Plant Physiol 2004, 136: 3457–3466. 10.1104/pp.104.050153PubMed CentralView ArticlePubMed
- Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E: A plant-derived recombinant human glucocerebrosidase enzyme-A preclinical and phase I investigation. PLoS One 2009, 4: e4792. 10.1371/journal.pone.0004792PubMed CentralView ArticlePubMed
- Benchabane E, Goulet C, Rivard D, Faye L, Gomord V, Michaud D: Preventing unintended proteolysis in plant protein bioreactors. Plant Biotechnol J 2008, 6: 633–648. 10.1111/j.1467-7652.2008.00344.xView ArticlePubMed
- Berg-Fussman A, Grace ME, Ioannou Y, Grabowski GA: Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J Biol Chem 1993, 268: 14861–14866.PubMed
- Beutler E, Grabowsky GA: Gaucher disease. In Molecular and metabolic basis of inherited diseases. 8th edition. Edited by: Scriver CR, Beudet A, Sly WS, Valle D. McGrow-Hill, New York; 2001:3635–3656.
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72: 248–254. 10.1016/0003-2697(76)90527-3View ArticlePubMed
- Brady RO, Kanfer JN, Shapiro D: Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 1965, 18: 221–225. 10.1016/0006-291X(65)90743-6View ArticlePubMed
- Brumshtein B, Wormald MR, Silman I, Futerman AH, Sussman JL: Structural comparison of differentially glycosylated forms of acid-β-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr D: Biol Crystallogr 2006, 62: 1458–1465. 10.1107/S0907444906038303View Article
- Chen G, Rothnie HM, He X, Hohn T, Fütterer J: Efficient transcription from the rice tungro bacilliform virus promoter requires elements downstream of the transcription start site. J Virol 1996, 70: 8411–8421.PubMed CentralPubMed
- Cox TM, Schofield JP: Gaucher’s disease: clinical features and natural history. In: Gaucher’s disease. Baillieres Clin Haematol 1997, 10: 657–689. 10.1016/S0950-3536(97)80033-9View ArticlePubMed
- Damiano AM, Pastores GM, Ware JE: The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998, 7: 373–386.View ArticlePubMed
- De Amicis F, Patti T, Marchetti S: Improvement of the pBI121 plant expression vector by leader replacement with a sequence combining a poly(CAA) and a CT motif. Transgenic Res 2007, 16: 731–738. 10.1007/s11248-006-9063-xView ArticlePubMed
- Ding J, Jia J, Yang L, Wen H, Zhang C, Liu W, Zhang D: Validation of a rice specific gene, sucrose phosphate synthase, used as the endogenous reference gene for qualitative and real-time quantitative PCR detection of transgenes. J Agric Food Chem 2004, 52: 3372–3377. 10.1021/jf049915dView ArticlePubMed
- Doran PM: Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol 2006, 24: 426–432. 10.1016/j.tibtech.2006.06.012View ArticlePubMed
- Doyle JJ, Doyle JL: Isolation of plant DNA from fresh tissue. Focus 1990, 12: 13–15.
- Edman P: Method for the determination of the amino acid sequence in peptides. Acta Chem Scand 1950, 4: 283–293.View Article
- Emanuelsson O, Brunak S, von Heijne G, Nielsen H: Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc 2007,2(4):953–971. 10.1038/nprot.2007.131View ArticlePubMed
- Fischer R, Schillberg S, Hellwig S, Twyman RM, Drossard J: GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv 2012, 30: 434–439.View ArticlePubMed
- Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A: New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 2004, 25: 147–151. 10.1016/j.tips.2004.01.004View ArticlePubMed
- Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO: Enzyme therapy in Type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995, 122: 33–39.View ArticlePubMed
- Hiei Y, Ohta S, Komari T, Kumashiro T: Efficient transformation of rice (Oryza sativa L.) mediated by Agrobacterium and sequence analysis of the boundaries of the T-DNA. Plant J 1994, 6: 271–282. 10.1046/j.1365-313X.1994.6020271.xView ArticlePubMed
- Hollak CE, Vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, Di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM: Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2009. 10.1016/j.bcmd.2009.09.006
- Humphrey BD, Huang N, Klasing KC: Rice expressing lactoferrin and lysozyme has antibiotic-like properties when fed to chicks. J Nutr 2002, 132: 1214–1218.PubMed
- Kawakatsu T, Yamamoto MP, Hirose S, Yano M, Takaiwa F: Characterization of a new rice glutelin gene GluD-1 expressed in the starchy endosperm. J Exp Bot 2008,59(15):4233–4245. 10.1093/jxb/ern265PubMed CentralView ArticlePubMed
- Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227: 680–685. 10.1038/227680a0View ArticlePubMed
- Lerouge P, Cabanes-Macheteau M, Rayon C, Fischette-Laine AC, Gomord V, Faye L: N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol Biol 1998, 38: 31–48. 10.1023/A:1006012005654View ArticlePubMed
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999, 282: 249–254.View Article
- Musetti R, Grisan S, Polizzotto R, Martini M, Paduano C, Osler R: Interactions between ‘Candidatus Phytoplasma mali’ and the apple endophyte Epicoccum nigrum in Catharanthus roseus plants. J Appl Microbiol 2011,110(3):746–756. 10.1111/j.1365-2672.2011.04937.xView ArticlePubMed
- Qu LQ, Takaiwa F: Evaluation of tissue specificity and expression strenght of rice seed component gene promoters in transgenic rice. Plant Biotechnol J 2004, 2: 113–125. 10.1111/j.1467-7652.2004.00055.xView Article
- Reggi S, Marchetti S, Patti T, De Amicis F, Cariati R, Bembi B, Fogher C: Recombinant human acid β-glucosidase stored in tobacco seeds is stable, active and taken up by human fibroblasts. Plant Molec Biol 2005, 57: 101–113. 10.1007/s11103-004-6832-xView Article
- Reynolds ES: The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 1963, 17: 208–212. 10.1083/jcb.17.1.208PubMed CentralView ArticlePubMed
- Schillberg S, Fischer R, Emans N: Molecular farming of recombinant antibodies in plants. Cell Mol Life Sci 2003, 60: 433–445. 10.1007/s000180300037View ArticlePubMed
- Shaaltiel Y, Barfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D: Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 2007, 5: 579–590. 10.1111/j.1467-7652.2007.00263.xView ArticlePubMed
- Siemiatkoski J, Lyubarskaya Y, Houde D, Houde D, Tep S, Mhatre R: A comparison of three techniques for quantitative carbohydrate analysis used in characterization of therapeutic antibodies. Carbohydr Res 2006, 341: 410–419. 10.1016/j.carres.2005.11.024View ArticlePubMed
- Takaiwa F, Ogawa M, Okita TW: Rice glutelins. In Seed proteins. Edited by: Shewry P, Casey R. Kluwer Academic Publishers, Dordrecht, FL; 1999:401–426.View Article
- Takaiwa F, Takagi H, Hirose S, Wakasa Y: Endosperm tissue is good production platform for artificial recombinant proteins in transgenic rice. Plant Biotechnol J 2007, 5: 84–92. 10.1111/j.1467-7652.2006.00220.xView ArticlePubMed
- Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R: Molecular pharming in plants: host system and expression technology. Trends Biotechnol 2003, 21: 570–578. 10.1016/j.tibtech.2003.10.002View ArticlePubMed
- Vitale A, Pedrazzini E: Recombinant pharmaceuticals from plants: the plant endomembrane system as bioreactor. Mol Interv 2005, 5: 216–225. 10.1124/mi.5.4.5View ArticlePubMed
- Yan X, Gonzales RA, Wagner GJ: Gene fusions of signal sequences with a modified β-glucuronidase gene results in retention of the β-glucuronidase protein in the secretory pathway/plasma membrane. Plant Physiol 1997, 115: 915–924. 10.1104/pp.115.3.915PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.